The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance

BJU International

Volumn 109, Issue 8, 2012, Pages 1170-1176

  Ayres, Benjamin E ^a   Montgomery, Bruce S I ^a   Barber, Neil J ^a   Pereira, Nicola ^a   Langley, Stephen E M ^b   Denham, Philippa ^a   Bott, Simon R J ^a  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Active surveillance; Prostate biopsy; Prostate cancer; Prostate specific antigen; Transperineal template prostate biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; ECHOGRAPHY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECTUM BIOPSY; TREATMENT OUTCOME;

AGED; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EQUIPMENT DESIGN; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PERINEUM; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENTINEL SURVEILLANCE;

EID: 84859466437     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10480.x     Document Type: Article

References (37)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9 (Pubitemid 41095147)
2. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90 (Pubitemid 34814727)
3. Johansson JE, Andren O, Andersson SO et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-9 (Pubitemid 38725420)
4. Bastian PJ, Carter BH, Bjartell A et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55: 1321-32
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
6. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7 (Pubitemid 37254930)
7. Steyerberg EW, Roobol MJ, Kattan MW et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177: 107-12 (Pubitemid 44879468)
8. Nakanishi H, Wang X, Ochiai A et al. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 2007; 110: 2441-7 (Pubitemid 350174929)
9. Ochiai A, Trpkov K, Yilmaz A, Donnelly B, Babaian RJ. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 2007; 177: 907-10 (Pubitemid 46216359)
10. Jeldres C, Suardi N, Walz J et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008; 54: 1306-13
11. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-5 (Pubitemid 39425375)
12. Roemeling S, Roobol MJ, Postma R et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. E ur Urol 2006; 50: 475-82 (Pubitemid 44189069)
13. van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009; 55: 1-8
14. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23: 8165-9 (Pubitemid 46211550)
15. Carter HB, Kettermann A, Warlick C et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178: 2359-65 (Pubitemid 350052183)
16. Dall'Era MA, Konety BR, Cowan JE et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112: 2664-70 (Pubitemid 351969209)
17. van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54: 1297-305
18. Hardie C, Parker C, Norman A et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956-60 (Pubitemid 40655686)
19. Choo R, Klotz L, Danioux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-9 (Pubitemid 34240696)
20. Eggener SE, Mueller A, Berglund RK et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009; 181: 1635-41
21. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
22. Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE. Extensive transperineal template biopsies of prostate: modified technique and results. Urology 2006; 68: 1037-41 (Pubitemid 44750129)
23. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
24. Berglund RK, Materson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-7
25. Suardi N, Capitanio U, Chun FK et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113: 2068-72
26. Suardi N, Briganti A, Gallina A et al. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 2010; 105: 1548-52
27. Ploussard G, Xylinas E, Salomon L et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009; 56: 891-8
28. Klotz L. Active surveillance with selective delayed intervention for favourable risk prostate cancer. Urol Oncol 2006; 24: 46-50 (Pubitemid 43097357)
29. Abouassaly R, Lane BR, Jones JS. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 2008; 71: 573-7 (Pubitemid 351442978)
30. Merrick GS, Taubenslag W, Andreini H et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 2008; 101: 1524-9 (Pubitemid 351704030)
31. Li H, Yan W, Zhou Y, Ji Z, Chen J. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. Urology 2007; 70: 1157-61 (Pubitemid 350297370)
32. Bott S, Langley S, Hindley R, Montgomery B. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction. BJU Int 2009; 103: 701
33. Bott SR, Young MP, Kellett MJ, Parkinson MC, Contributors to the UCL Hospitals ' Trust Radical Prostatectomy Database. Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002; 89: 886-9
34. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009; 182: 2274-8
35. Ng MK, Van As N, Thomas K et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 2009; 103: 872-6
36. Ross AE, Loeb S, Landis P et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-6
37. Bill-Axelson A, Holmberg L, Filén F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54